Autoimmune clinical trials commonly use an integrated suite of biomarker services to characterize disease activity,immune response,and treatment effect. Core services include immune monitoring through high-parameter flow cytometry,mass cytometry (CyTOF),and ELISpot;multiplex cytokine and autoantibody profiling via MSD,Olink,and Ella platforms;proteomics and bioanalytical mass spectrometry for inflammatory protein quantification;genomics,including single-cell transcriptomics and TCR/BCR repertoire sequencing;and multiplexed histopathology with digital image analysis.
\nCellCarta delivers these services across our integrated,globally harmonized,and owned facilities,with panels developed for lupus,rheumatoid arthritis,psoriasis,myasthenia gravis,and transplant.
"},{"faq_question":"What should sponsors look for when evaluating a biomarker CRO for an autoimmune program?","faq_answer":"Sponsors should evaluate four dimensions:scientific depth in immune-mediated disease biology,breadth of validated assay platforms (high-parameter flow and mass cytometry,multiplex immunoassays,mass spectrometry,multiplexed histopathology,single-cell and repertoire sequencing),modality coverage across small molecules,biologics,and emerging cell therapies,and global lab harmonization supporting multi-region trials.
\nCellCarta brings 25+ years of immunology biomarker experience,750+ employees,and panels developed for lupus,RA,psoriasis,myasthenia gravis,and transplant.
"},{"faq_question":"Why is patient stratification and immune monitoring so important in autoimmune clinical trials?","faq_answer":"Autoimmune diseases are heterogeneous. Patients with the same clinical diagnosis often differ markedly in their underlying immune biology,a leading cause of trial failures and inconsistent response rates. Robust immune monitoring and biomarker-driven patient stratification help identify responder subsets,demonstrate the mechanism of action,support dose selection,and de-risk later-stage development. Validated approaches include high-parameter flow cytometry,multiplex cytokine profiling,autoantibody panels,and tissue immune characterization.
\nCellCarta supports stratification strategies across lupus,RA,psoriasis,myasthenia gravis,and transplant programs.
"},{"faq_question":"How does a specialized CRO support autoimmune trials across multiple indications and geographies?","faq_answer":"A specialized CRO supports multi-indication,multi-region autoimmune trials through globally harmonized labs,standardized assay platforms,and cross-site bridging studies that confirm reproducibility. This allows sponsors to apply a consistent biomarker strategy across indications (lupus,rheumatoid arthritis,psoriasis,myasthenia gravis,transplant,GVHD) while collecting data that withstands global regulatory review.
\nCellCarta operates 8 globally harmonized facilities and has supported autoimmune trials across major immune-mediated indications,with quality systems aligned to international submission requirements.
"},{"faq_question":"How early should sponsors engage a biomarker CRO in an autoimmune development program?","faq_answer":"Sponsors typically benefit from engaging a biomarker CRO during late discovery or early translational development,before first-in-human studies,to align biomarker strategy with the asset’s mechanism,target pathway,and intended patient population. Early engagement allows time to develop and validate fit-for-purpose assays,design a patient stratification strategy,and plan immunogenicity and pharmacodynamic monitoring that will support later regulatory submissions. Late engagement often constrains assay choice and limits stratification feasibility.
\nCellCarta partners with sponsors from discovery through commercialization across autoimmune programs.
"}]}#-supreme-cellcarta-indications-4-737{cards-data:[{"image":"https://cellcarta.com/wp-content/uploads/2026/07/Lupus.jpg","image_alt":"Lupus anti-dsDNA antibody complement C3 B T lymphocyte monitoring","title":"Lupus","description":"Track anti-dsDNA antibodies,complement C3,and B and T lymphocyte populations across trial phases."},{"image":"https://cellcarta.com/wp-content/uploads/2026/06/Cta-banner100.jpg","image_alt":"Myasthenia gravis anti-AChR anti-MuSK antibody B-cell subset monitoring","title":"Myasthenia Gravis","description":"Anti-AChR and anti-MuSK antibody quantification with complement pathway and B-cell subset monitoring."},{"image":"https://cellcarta.com/wp-content/uploads/2026/07/Psoriasis-53.jpg","image_alt":"Psoriasis IL-17A tissue immune characterization anti-drug antibody monitoring","title":"Psoriasis","description":"IL-17A quantification,tissue-based immune characterization,and anti-drug antibody monitoring."},{"image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-12-2-scaled.jpg","image_alt":"Rheumatoid arthritis cytokine profiling JAK inhibitor pathway phenotyping","title":"Rheumatoid Arthritis","description":"Cytokine profiling,anti-CCP and RF monitoring,and JAK inhibitor pathway phenotyping across visits."},{"image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-59-scaled.jpg","image_alt":"Transplant GVHD T-lymphocyte NK B-cell Treg anti-donor HLA antibody monitoring","title":"Transplant/GVHD","description":"T-lymphocyte,NK cell,and B-cell phenotyping alongside anti-donor HLA antibody and Treg monitoring."}]}#-supreme-cellcarta-overview-3-737{stats-data:[{"number":"25+","label":"Years of expertise"},{"number":"8","label":"Global labs"},{"number":"750+","label":"Employees"}]}#-supreme-cellcarta-tab-content-5-737{tabs-data:[{"tab_title":"Immune Cell Analysis","content_title":"","content_body":"Whether measuring immune dysregulation or your drug’s mechanism of action,our immune monitoring capabilities can provide the depth and reproducibility required,including:
\nFor studies investigating B-cell aplasia,CellCarta has validated a high-sensitivity TBNK assay that can be readily deployed for the exploratory endpoint.
\nTo monitor B-cell reset and further characterize the B-cell populations,we can develop a custom flow cytometry panel aligned to your program’s requirements. Single-cell BCR sequencing may also be implemented to identify key immune reset metrics.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-49-scaled.jpg","image_alt":""},{"tab_title":"Image Diseased Tissue","content_title":"","content_body":"Track disease activity and therapeutic effect in situ using techniques ranging from singleplex,multiplex and,hyperplex immunohistochemistry (IHC),in situ hybridization (ISH),and spatial analysis.
\nOur in-house pathologists specialize in immune-mediated tissue pathology and spatial characterization of inflammation. AI-powered digital algorithms are used to generate rich multi-layered data sets.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/07/Histopathology-tab-720.jpg","image_alt":"Histopathology multiplexed IHC immunofluorescence digital pathology AI-assisted analysis"},{"tab_title":"Molecular Characterization","content_title":"","content_body":"When researchers need to characterize immune cell subpopulations,identify disease-relevant signatures,and track therapeutic mechanisms at the molecular level,CellCarta's genomics capabilities are built to meet the occasion.
\nOur service portfolio includes:
\nCellCarta's proteomics capabilities support both large-scale discovery and validated quantification of inflammatory cytokines,chemokines,proteins and drug-related analytes across plasma,serum,and tissue sample types using mass spectrometry.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-16-2-scaled.jpg","image_alt":"Proteomics mass spectrometry inflammatory proteins auto-antibodies autoimmune analytes"}]}#-supreme-cellcarta-technology-6-737{cards-data:[{"card_title":"Flow Cytometry","card_image":"https://cellcarta.com/wp-content/uploads/2026/06/Flow-Cytometry-Services-118.jpg","image_alt":"Flow cytometry BD Lyric Cytek Aurora high-parameter immune cell profiling","card_description":"Our spectral and conventional flow cytometry platforms,including the BD Lyric and Cytek Aurora,deliver high-resolution immune cell profiling with up to 40 parameters per cell. Standardized across our global laboratory network,these instruments ensure site-to-site consistency for multi-site autoimmune trials.
","card_link":"/platforms/flow-cytometry/","card_link_text":"Explore flow cytometry"},{"card_title":"Immunoassay Platforms","card_image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-38-2-scaled.jpg","image_alt":"Immunoassay MSD Olink Ella ELISA multiplex cytokine biomarker profiling","card_description":"Quantify dozens to hundreds of immune biomarkers simultaneously using MSD,Olink,Ella,and ELISA platforms. Our multiplex capabilities enable broad cytokine profiling,pharmacodynamic assessment,and biomarker discovery from minimal sample volume to deliver high-quality data.
","card_link":"/capabilities/immunoassay-services/","card_link_text":"Explore immunoassays"},{"card_title":"Mass Spectrometry","card_image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-16-2-1-scaled.jpg","image_alt":"Mass spectrometry Immuno-MRM proteomics protein biomarker serum plasma tissue","card_description":"Our Immuno-MRM and advanced proteomics platforms enable precise quantification of protein biomarkers in serum,plasma,and tissue. Mass spectrometry-based approaches complement immunoassays by providing orthogonal confirmation and measuring analytes at the peptide level,avoiding common issues of protein affinity purification.
","card_link":"/platforms/mass-spectrometry/","card_link_text":"Explore mass spectrometry"}]}